Adalimumab biosimilar (Sandoz)

阿达木单抗生物类似药（Sandoz）

Report date: 2026/05/26 20:00:28

Base Information

Drug NameAdalimumab biosimilar (Sandoz)
Drug Alias NameAdalimumab-adaz阿达木单抗生物仿制药（Sandoz）HyrimozHalimatozHefiya +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisPolyarticular Juvenile Idiopathic Arthritis +[12] 
Global Approved IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisPolyarticular Juvenile Idiopathic Arthritis +[12] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2018/07/26
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSandoz
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma AgSandoz IncSandoz Gmbh
Inactive CompaniesSandozHexal Ag
Active IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisPolyarticular Juvenile Idiopathic Arthritis +[11] 
Inactive IndicationsUveitis

Other Information

ATC CodeL04AB04
Related LinksN/A